14-16 November 2018

Boston

Geneos Therapeutics

Geneos Therapeutics
Industry Partner

Geneos Therapeutics is harnessing the power of advances in genomics, artificial intelligence and cancer immunotherapy to develop patient specific, tumor neoantigen targeted immunotherapies against cancer.  The company, created as a spinout of Inovio Pharmaceuticals, has exclusively licensed Inovio’s DNA based ASPIRE® (Antigen Specific Immune Responses) immunotherapy platform for individualized treatments.  The versatile platform has demonstrated clinically the induction of antigen specific CD8 T cells and CTL and TIL activity across a variety of therapeutic settings.  Geneos’ neoantigen approach is established to deliver large neoantigenic payloads and benefits significantly from the safety profile, potency, and rapid manufacturing turnaround times of plasmid DNA products